You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Drug and gene targeting to the brain with molecular trojan horses
|
|---|---|
| Published in |
Nature Reviews Drug Discovery, February 2002
|
| DOI | 10.1038/nrd725 |
| Pubmed ID | |
| Authors |
William M. Pardridge |
| Abstract |
Getting drugs and genes into the brain is a tall order. This is because the presence of the blood-brain barrier prevents many molecules from crossing into the brain. Overcoming this problem will have a profound effect on the treatment of many neurological disorders, allowing larger water-soluble molecules to pass into the brain. Transport vectors, such as endogenous peptides, modified proteins or peptidomimetic monoclonal antibodies, are one way of tricking the brain into allowing these molecules to pass. This article will review such molecular Trojan Horses, and the progress that has been made in the delivery of drugs and genes to the brain. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 342 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | <1% |
| Canada | 2 | <1% |
| Netherlands | 1 | <1% |
| India | 1 | <1% |
| Switzerland | 1 | <1% |
| Denmark | 1 | <1% |
| Germany | 1 | <1% |
| Spain | 1 | <1% |
| China | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 330 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 69 | 20% |
| Researcher | 58 | 17% |
| Student > Master | 56 | 16% |
| Student > Bachelor | 39 | 11% |
| Student > Doctoral Student | 17 | 5% |
| Other | 59 | 17% |
| Unknown | 44 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 80 | 23% |
| Biochemistry, Genetics and Molecular Biology | 40 | 12% |
| Medicine and Dentistry | 40 | 12% |
| Chemistry | 37 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 28 | 8% |
| Other | 52 | 15% |
| Unknown | 65 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#1,682,881
of 23,445,423 outputs
Outputs from Nature Reviews Drug Discovery
#832
of 3,425 outputs
Outputs of similar age
#2,937
of 125,303 outputs
Outputs of similar age from Nature Reviews Drug Discovery
#6
of 19 outputs
Altmetric has tracked 23,445,423 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,425 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.6. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 125,303 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.